Advisory body on drug misuse to provide framework on medical cannabis by end of 2019 The Pharmaceutical Journal, 9 MAY 2019, By Julia Robinson The Pharmaceutical Journal, May 2019, Vol 302, No 7925, online | DOI: 10.1211/PJ.2019.20206487 https://www.pharmaceutical-journal.com/news-and-analysis/news/advisory-body-on-drug-misuse-to-provide-framework-on-medical-cannabis-by-end-of-2019/20206487.article?firstPass=false Source: Charlie Milligan Roger Knaggs says he isn’t surprised about the lack of medical cannabis prescriptions since its reclassification, warning that it will continue until prescribers have a clearer idea about what they should be prescribing The Advisory Council on the Misuse of Drugs (ACMD) has been asked to provide an outline framework on medical cannabis by the end of 2019, with the aim of having an initial view [...]
Lire la suiteCannabis Where are we and where are we going ? Bilan sur les statuts du cannabis dans le monde Le groupe Edison a publié une revue sur le statut du cannabis dans le monde. Où sommes-nous et où allons-nous? EDISON Healthcare, 30 April 2019 The cannabis sector is relatively broad, spanning FDA-approved drugs toconsumer products. Both markets are still at a fraction of their potential peak sizes due to laws forbidding the use of cannabis and also regulatory hesitance to approve drugs with related active ingredients. Worldwide sales for all regulator-approved cannabinoid therapeutics were only $53m in 2018 while the total legal cannabis market [...]
Lire la suiteIACM-Bulletin du 31 Mai 2019 http://www.cannabis-med.org/french/bulletin/ww_fr_db_cannabis_artikel.php?id=488#1 Science/Homme: D'après une étude clinique, le CBD réduit le besoin impérieux d'abstinence chez les sujets toxicodépendants à l'héroïne Etats-Unis: Le Dakota du Nord décriminalise l'usage du cannabis chez les adultes, jusqu'à aujourd’hui c’était 10 États qui avaient légalisé l'usage du cannabis pour les adultes Gréce: Six licences accordées à des sociétés pour la culture de cannabis Science/Animal: Selon un essai clinique contrôlé, le CBD est d'efficacité modérée dans la réduction des crises convulsives chez les chiens épileptiques En bref Un coup d'œil sur le passé Science/Homme: [...]
Lire la suiteMDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials Michael C. Mithoefer, Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin Psychopharmacology, 2019 https://doi.org/10.1007/s00213-019-05249-5 Abstract Background : Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Methods : Six randomized, double-blind, controlled clinical trials [...]
Lire la suiteCANNABIS EN TÊTE A propos du Dossier Central publié dans le N°237 de la Revue SANTÉ MENTALE "SCHIZOPHRÉNIE ET CANNABIS" - - - - - - - - - - DOPAMINE #05 (MAI 2019) Sans créer de lien de causalité à la vas-vite, difficile de ne pas associer schizophrénie et usage de cannabis puisqu'un quart des patients souffrants de cette pathologie consomment régulièrement un produit qui n'est peut-être pas entré dans leur vie par hasard ou du moins qu'ils ont adopté pour soulager certains symptômes tout en en aggravant d'autres... Quant à la part de responsabilité du cannabis dans l'apparition d'une schizophrénie, un certain nombre [...]
Lire la suiteEfficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suiteCannabis thérapeutique : «Tous les voyants sont au vert» Par Charles Delouche — 29 mai 2019 à 18:50 Libération Alors que l’Agence nationale du médicament doit rendre son projet d'expérimentation du cannabis thérapeutique fin juin, le Sénat a débattu du sujet ce mercredi à l’initiative d’Esther Benbassa, sénatrice EE-LV de Paris. Battre le fer tant qu’il est chaud. C’est l’idée qui animait le débat sans vote qui s’est déroulé ce mercredi au Sénat autour du cannabis thérapeutique à l'initiative d'Esther Benbassa, sénatrice Europe Ecologie-les Verts (EE-LV) de Paris. La veille, une conférence de presse était organisée aux côtés de [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suiteDissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. Freeman, Amanda Feilding, David J. Nutt and H. Valerie Curran Journal of Psychopharmacology, 2019, 1–9 DOI: 10.1177/0269881119841568 journals.sagepub.com/home/jop Abstract Background : Two major constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. Aims : We examined the effects of two strains of cannabis and placebo on the human brain’s resting-state networks [...]
Lire la suitePsychedelic therapy in the Czech Republic : A theoretical concept or a realistic goal ? Zuzana Postranecka, Čestmir Vejmola and Filip Tyls Journal of Psychedelic Studies DOI: 10.1556/2054.2019.003 Abstract Psychedelic research has been associated with the Czech Republic since the early 19th century and, after a long period of involuntary dormancy, it has recently gained new opportunities to follow up on its roots and evolve. This article briefly describes the history of psychedelic research in the Czech Republic, summarizes the role of the UN Drug Conventions, and discusses the Czech and international legislation pertaining to psychedelics. The discussion focuses on the dependence/abuse potential of classical [...]
Lire la suite